Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, 69120 Heidelberg, Germany.
Cells. 2019 Feb 10;8(2):142. doi: 10.3390/cells8020142.
In highly aggressive malignancies like pancreatic cancer (PC), patient-derived tumor models can serve as disease-relevant models to understand disease-related biology as well as to guide clinical decision-making. In this study, we describe a two-step protocol allowing systematic establishment of patient-derived primary cultures from PC patient tumors. Initial xenotransplantation of surgically resected patient tumors (n = 134) into immunodeficient mice allows for efficient in vivo expansion of vital tumor cells and successful tumor expansion in 38% of patient tumors (51/134). Expansion xenografts closely recapitulate the histoarchitecture of their matching patients' primary tumors. Digestion of xenograft tumors and subsequent in vitro cultivation resulted in the successful generation of semi-adherent PC cultures of pure epithelial cell origin in 43.1% of the cases. The established primary cultures include diverse pathological types of PC: Pancreatic ductal adenocarcinoma (86.3%, 19/22), adenosquamous carcinoma (9.1%, 2/22) and ductal adenocarcinoma with oncocytic IPMN (4.5%, 1/22). We here provide a protocol to establish quality-controlled PC patient-derived primary cell cultures from heterogeneous PC patient tumors. In vitro preclinical models provide the basis for the identification and preclinical assessment of novel therapeutic opportunities targeting pancreatic cancer.
在胰腺癌 (PC) 等侵袭性极强的恶性肿瘤中,患者来源的肿瘤模型可以作为与疾病相关的模型,用于了解疾病相关的生物学特性,并为临床决策提供指导。在这项研究中,我们描述了一种两步法方案,可系统地从 PC 患者肿瘤中建立患者来源的原代培养物。将手术切除的患者肿瘤(n = 134)初始异种移植到免疫缺陷小鼠中,可有效地在体内扩增有活力的肿瘤细胞,并使 38%的患者肿瘤(51/134)成功扩增。扩增的异种移植物紧密重现了与其匹配的患者原发肿瘤的组织学结构。对异种移植物进行消化,并随后进行体外培养,在 43.1%的病例中成功地产生了纯上皮细胞来源的半贴壁 PC 培养物。所建立的原代培养物包括多种不同病理类型的 PC:胰腺导管腺癌 (86.3%,19/22)、腺鳞癌 (9.1%,2/22) 和伴嗜酸细胞性 IPMN 的导管腺癌 (4.5%,1/22)。我们在此提供了一种从异质性 PC 患者肿瘤中建立质量控制的 PC 患者来源原代细胞培养物的方案。体外临床前模型为鉴定和临床前评估针对胰腺癌的新型治疗机会提供了基础。